Ovarian Cancer Diagnostics Market is projected to reach USD 1,836.03 million during the forecast period to 2029

Rajaas

posted on 1 year ago — updated on 1 second ago

221
views

The tests and procedures used to diagnose ovarian cancer includes the pelvic exam, imaging tests, blood tests, surgery and among others. During a pelvic exam, the doctor inserts gloved fingers into the vagina and simultaneously presses a hand on your abdomen in order to feel (palpate) your pelvic organs. The doctor also visually examines the vagina, cervix and external genitalia. Ovarian cancer is a type of cancer that begins in the ovaries, there are several types of ovarian cancer, the most common of which is epithelial ovarian cancer. The primary cause of this type of cancer is uncontrollable cell growth in the ovarian tissue, and it is one of the leading causes of death in women worldwide. It is the fifth leading cause of cancer death in women worldwide, and the tenth leading cause of cancer death in women in the United States.

Data Bridge Market Research analyses that the ovarian cancer diagnostics market which was USD 1,084.7 million in 2021, is expected to reach USD 1,836.03 million by 2029, at a CAGR of 6.80% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Get Sample PDF Report – https://www.databridgemarketresearch.com/reports/global-ovarian-cancer-diagnostics-market

Some of the major players operating in the ovarian cancer diagnostics market are:

Abbott (U.S.) F. Hoffmann-La Roche Ltd (Switzerland) QIAGEN (Germany) Quest Diagnostics Incorporated. (U.S.) Hologic, Inc. (U.S.) Arbor Vita Corporation (U.S.) Guided Therapeutics, Inc. (U.S.) CooperSurgical Inc (U.S.) BD (U.S.) Cardinal Health (U.S.) Siemens Healthcare Private Limited (Germany) Zilico (U.K.) GenomeMe Lab Inc. (Canada) Exact Sciences Corporation (U.S.) Fujirebio (Japan), Advaxis Inc. (U.S.) Pfizer Inc. (U.S.) GlaxoSmithKline plc. (U.K.) Bristol-Myers Squibb Company (U.S.) Merck Co., Inc (U.S.) Global Ovarian Cancer Diagnostics Market Dynamics

Drivers

Novel biosensor for monitoring ovarian cancer tumors will promote growth Carcinoma antigen 125 (CA 125) has been identified as a clinical glycoprotein/biomarker for the early detection of ovarian cancer. As a result, accurate carcinoma antigen 125 determination is critical for cancer diagnosis and treatment. To detect the carcinoma antigen 125 biomarker in human plasma samples, a new biosensor was developed. The surface morphology of the electrode was investigated using field emission scanning electron microscopy (FE-SEM) and energy dispersive spectroscopy (EDS). Transmission electron microscopy (TEM) was used to investigate the mechanism of nano-ink production. The formation of an antigen-antibody complex was also monitored using differential pulse voltammetry (DPV). For detecting the carcinoma antigen 125 biomarker, the designed immunosensor performed well, with excellent specificity and sensitivity. Therefore, based on the results, it is concluded that immunosensor has the potential to be employed in the early detection of ovarian cancer in clinical studies. These all are the novel biosensors which helps the market to grow.

Increased prevalence of ovarian cancer in the number of elderly women The growing economies of both developed and developing countries are driving the expansion of healthcare. As a result, they are assisting in the advancement of the global ovarian cancer diagnostics market. The global ovarian cancer diagnostics market is expected to grow as the incidence of ovarian cancer rises, new treatments and therapies become more widely available, and healthcare spending rises. Ovarian cancer has become more common as the female population has aged. The ovarian cancer market is being driven forward by rising ovarian cancer prevalence, the introduction of new medications and therapies, increased healthcare expenditure, and increased government funding.

Opportunities

Rising development to propel growth Drugs such as Bevacizumab (Avastin) and Pazopanib (Votrient) are expected to stimulate the market, which is currently dominated by generics like paclitaxel and carboplatin. The development of new medications to treat this type of cancer is expected to significantly benefit the market. Ongoing research and development to develop effective treatment interventions for various disorders supports the global ovarian cancer diagnostics market.

To Obtain More Insights into Market Analysis, Browse Research Report Summary @– https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-ovarian-cancer-diagnostics-market

Global Ovarian Cancer Diagnostics Market Scope

The ovarian cancer diagnostics market is segmented on the basis of diagnosis type, cancer type and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis Type

Imaging CT Scan Ultrasound Positron Emission Tomography Scan Magnetic Resonance Imaging (MRI) Scan Others Biopsy Image Guided Biopsy Fine Needle Aspiration Biopsy Others Blood Test BRCA Carcinoma Antigen 125 Estrogen Receptor/Progesterone Receptor HER2 Carcinoembryonic Antigen Test Kirsten Rat Sarcoma virus Mutation Others Others Cancer Type

Germ Cell Tumor Stromal Cell Tumor Epithelial Tumor Others End-use

Cancer Diagnostic Centers Hospital Laboratories Research Institutes Others Ovarian Cancer Diagnostics Market Regional Analysis/Insights

The ovarian cancer diagnostics market is analysed and market size insights and trends are provided by country, diagnosis type, cancer type and end use as referenced above. The countries covered in the ovarian cancer diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the ovarian cancer diagnostics market due to the rising awareness about the disease and availability of advanced diagnostic technology. Awareness among the people about the disease is also one of the major factors boosting the market in this region. Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to rise in prevalence of ovarian cancer.

Browse Complete TOC at- https://www.databridgemarketresearch.com/toc/?dbmr=global-ovarian-cancer-diagnostics-market

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter’s five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.